LEGION™ Primary TKS with VERILAST™ Bearing Surface
LEGION™ Primary TKS with VERILAST™ Bearing Surface: All study subjects will be treated with LEGION™ Primary TKS with VERILAST™ Bearing Surface as per standard clinical practice.
Study summary
LEGION™ Primary Total Knee System is CE-marked and marketed in all study regions. This study serves as post-market surveillance for LEGION™ Primary Total Knee System with the VERILAST™ bearing surface (OXINIUM™ femoral component with highly cross-linked polyethylene tibial insert).
All study subjects will receive a LEGION™ Primary Total Knee System with VERILAST™ bearing surface and the results will be analysed against historical data from patients who received a Genesis II knee replacement.
Eligibility
Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria:
* Subject requires primary TKA and has elected to use the LEGION™ Primary TKS with VERILAST™.
* Subject requires primary TKA due to degenerative joint disease (primary osteoarthritis, post-traumatic arthritis, avascular necrosis, rheumatoid arthritis).
* Subject is of legal age to consent, agrees to consent to and to follow the study visit schedule (as defined in the study protocol and informed consent form), by signing the EC approved informed consent form.
* Routine radiographic assessment is possible.
* Subject plans to be available through ten (10) years postoperative follow-up.
* Subject is 18-75 years of age at the time of surgery.
Exclusion Criteria:
* Age \> 75 years at the time of surgery.
* Subjects with immunosuppressive disorders.
* Subject has severe pronation of the ipsilateral foot or any other relevant clinical condition contributing to abnormal ambulation (including but not limited to ankle fusion, ankle arthroplasty, previous hip fracture, ipsilateral hip arthritis resulting in flexion contracture).
* Subject has undergone a previous major surgery to the study knee (including osteotomy, fracture fix, medial or lateral ligament surgery).
* Subject has active infection or sepsis (treated or untreated).
* At the time of enrollment, subject has one or more of the following arthroplasties that are not fully healed and well-functioning, as determined by the Investigator:
* Ipsilateral or contralateral primary total hip arthroplasty or hip resurfacing arthroplasty.
* Contralateral primary total knee or unicondylar knee arthroplasty.
* Subject has presence of malignant tumor, metastatic, or neoplastic disease.
* Subject has conditions that may interfere with the TKA survival or outcome (i.e., Paget's or Charcot's disease, muscular atrophy, uncontrolled diabetes, moderate to severe renal insufficiency or neuromuscular disease).
* Subject has any acute or chronic morbidity of vascular origin that, in the opinion of the Investigator, is likely to compromise successful treatment or compliance to follow-up visits.
* Subject has inadequate bone stock to support the device (severe osteopenia, family history of severe osteoporosis or osteopenia).
* Subject has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study.
* Subject has a Body Mass Index (BMI) \>40.0.
* Subject requires revision TKA.
* Subject is expected to require bilateral TKA within 1 year following study knee replacement.
* Subject does not understand the language used in the Informed Consent Form.
* Subject is enrolled in another clinical study at the same time.
Primary outcome measure(s)
Survival — 10 years Non-inferiority of survival of Legion Primary with Verilast compared to a literature reference rate of 92.6% for Genesis II TKS
Trial sites (7)
Facility
City
Region
Status
Evangelisches Krankenhaus Wien
Vienna
Austria
Orthopadische Krankenhaus Gersthof
Vienna
Austria
AMEOS Klinikum Seepark Geestland
Langen
Kreis Geestland
OrthoCentrum
Hamburg
Germany
CaritasKlinikum St. Joseph Saarbrücken-Dudweiler
Saarbrücken-Dudweiler
Germany
KniePraxis Prof. Dr. Tibesku
Straubing
Germany
Servicio de C.O.T. Hospital Clínico Universitario de Santiago de Compostela
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.